You are here

Canadian Notice of Compliance Issued for Eligard, Prostate Cancer Treatment Now Available

FORT COLLINS, Colo., Nov. 7 /PRNewswire-FirstCall/ -- Atrix Laboratories, Inc. announced today that Sanofi-Synthelabo Canada, Atrix's licensee, has received notice of compliance (NOC) from the Therapeutic Products Directorate of Health Canada for Eligard® 7.5mg and 22.5mg (leuprolide acetate for injection), one- and three-month sustained-release prostate cancer products. NOC permits these products to be sold in Canada. Sanofi-Synthelabo Canada will be responsible for marketing the products in Canada.

"As director of technical affairs, it is my responsibility to leverage our core U.S. New Drug Application to build a worldwide franchise for Eligard," said Elyse Wolff, director of technical affairs. "This is the first ex-U.S. approval and we look forward to repeating this success throughout the world."

The Canadian market opportunity for hormone therapy products for prostate cancer is approximately $60 million with a similar competitive landscape as the U.S.

Sustained levels of leuprolide decreases testosterone levels to suppress tumor growth in patients with prostate cancer. The liquid Eligard products, using Atrix's proprietary Atrigel® sustained-release drug delivery technology, are injected subcutaneously with a small gauge needle, forming a solid implant in the body that slowly releases leuprolide as the implant is bioabsorbed.

Eligard 30mg, four-month prostate cancer product is currently under review by Health Canada. Eligard 7.5mg, 22.5mg and 30mg products for advance prostate cancer are currently marketed in the U.S. by Sanofi-Synthelabo, Inc.

Eligard 7.5mg and 22.5mg, like other hormonal treatments for prostate cancer, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment. Response to these products should be monitored by measuring serum concentrations of testosterone and prostate specific antigen periodically.

Source: Atrix Laboratories, Inc.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs